VFA
NBSE

Virtus Fund Advisers’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Virtus Fund Advisers’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4
Closed -$17K – 2036
2014
Q2 		$17K Buy
+4
New +$15.1K ﹤0.01% 2541

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtus Fund Advisers's NBSE Position: Q3 2014 in Review

Virtus Fund Advisers sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2014, closing a stake of 4 shares — an estimated $17K sold.

Virtus Fund Advisers first reported a position in NBSE in Q2 2014 and held it in 1 quarter. The position peaked at $17K in Q2 2014. 52 funds tracked by Wall St. Rank hold NBSE as of Q3 2014.

  • Virtus Fund Advisers reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 4 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $17K.
  • Virtus Fund Advisers first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's NeuBase Therapeutics, Inc. Common Stock position peaked at $17K in Q2 2014.
  • 52 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.